Xbrane Biopharma AB

Xbrane Biopharma has provided an update on its long-gestating filing for a biosimilar version of Genentech’s Lucentis (ranibizumab) in the US. The latest word from the US Food and Drug Administration

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Alvotech has struck a deal worth SEK275m ($27.0m) to acquire Xbrane BioPharma’s R&D operations in Sweden – based in Campus Solna, at the Karolinska Institute outside Stockholm – as well as the fir